12 eredmények
CROSS REFERENCE TO RELATED APPLICATIONS
This application is a U.S. national stage application of International Application No. PCT/EP2015/051657, filed on Jan. 28, 2015, which claims priority to European Application No. 14152785.3, filed on Jan. 28, 2014. The contents of these previously filed
FIELD OF THE INVENTION
The invention relates to the field of medicine, such as the use of exendins, exendin agonists, and exendin analog agonists to lower plasma lipid levels and improve cardiovascular health in patients.
BACKGROUND OF THE INVENTION
Research from experimental animals, laboratory
BACKGROUND OF THE INVENTION
1. Field of the Invention
The invention relates generally to prevention and treatment of atherosclerosis, myocardial infarction and related conditions such as peripheral vascular disease and ischemic stroke, and specifically to drugs that increase levels of HDL.
2.
CROSS-REFERENCE TO RELATED APPLICATIONS
The present application is a national phase entry under 35 U.S.C. .sctn.371 of International Application No. PCT/CN2013/074739, filed on Apr. 25, 2013, published in Chinese, which claims priority from Chinese Patent Application No. 201210125154.4, filed Apr.
FIELD OF THE INVENTION
The present invention relates to methods for predicting and following illnesses. More particularly, the present invention relates to the diagnosis of preeclampsia and other diseases.
BACKGROUND OF THE INVENTION
Vascular disease is often related to the composition of blood
FIELD OF THE INVENTION
This invention relates to compounds that inhibit the secretion of apolipoprotein B, and to methods of treating and/or preventing atherosclerosis, obesity, diabetes, hyperlipidemia, hyperlipoproteinemia, hypercholesterolemia, hypertriglyceridemia, hypoalphalipoproteinemia,
FIELD OF THE INVENTION
This invention relates to compounds that inhibit the secretion of apolipoprotein B, and to methods of treating and/or preventing atherosclerosis, obesity, diabetes, hyperlipidemia, hyperlipoproteinemia, hypercholesterolemia, hypertriglyceridemia, hypoalphalipoproteinemia,
CROSS-REFERENCE TO RELATED APPLICATIONS
This application is a 371 U.S. National Stage of International Application No. PCT/AU2013/001310, filed Nov. 13, 2013. This application claims the benefit of Australian Patent Applications Nos. 2012904937, filed Nov. 13, 2012 and 2012905406, filed Dec. 11,
RELATED APPLICATION
This application claims priority to U.S. Provisional Application No. 61/669,763, filed Jul. 10, 2012, the contents of which are incorporated herein by reference in its entirety.
BACKGROUND OF THE INVENTION
Diabetes mellitus has become pandemic and according to a forecast by the
BACKGROUND OF THE INVENTION
Diabetes mellitus has become pandemic and according to a forecast by the World Health Organization, there will be a sharp increase in the number of diabetic patients by the year 2030. This is an ominous forecast, because managing the long-term complications of diabetes,
BACKGROUND OF THE INVENTION
Diabetes mellitus has become pandemic and according to a forecast by the World Health Organization, there will be a sharp increase in the number of diabetic patients by the year 2030. This is an ominous forecast, because managing the long-term complications of diabetes,
FIELD OF THE INVENTION
The present invention relates to medicinal compositions, particularly to combinations of botanical extracts for promoting cardiovascular health.
BACKGROUND OF THE INVENTION
Cardiovascular disease (CVD), including coronary heart disease, atherosclerosis, stroke, myocardial